CHF 5993
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Analyst Outlook
Datamonitor Healthcare forecasts that should CHF 5993 (beclometasone/formoterol/glycopyrrolate;
Chiesi Farmaceutici) be approved and launched, it will be used in patients with very severe chronic
obstructive pulmonary disease (COPD) who are currently using multiple inhalers. While CHF 5993 has
the potential to be the first-to-market triple combination therapy in Europe, Datamonitor Healthcare
believes that its commercial prospects largely depend on Chiesi Farmaceutici partnering with a more
experienced player in the respiratory market. With the backing of a more experienced player, Chiesi
Farmaceutici could access a wider market for the drug, including the US, which will be key for its
commercial success.
Drug Overview
CHF 5993 is a fixed triple combination product consisting of glycopyrrolate, which is a long-acting
muscarinic antagonist (LAMA), formoterol, which is a long-acting beta 2 agonist (LABA), and
beclometasone, which is an inhaled corticosteroid (ICS). CHF 5993 is in Phase III development for the
treatment of severe to very severe COPD.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 CHF 5993 : Chronic obstructive pulmonary disease
LIST OF FIGURES
8 Figure 1: CHF 5993 for COPD – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of CHF 5993 for COPD
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of CHF 5993 for COPD
LIST OF TABLES
4 Table 1: CHF 5993 drug profile
6 Table 2: Phase III clinical trials for CHF 5993 in COPD
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
FF/UMEC/VI 
Sign up to the